Link Technologies secures exclusive license for ultra sensitive diagnostic probes
Deal marks the start of ongoing collaboration between Link and The University of Manchester
Link Technologies Ltd has announced an exclusive license deal with The University of Manchester Intellectual Property Limited (UMIP). Under the terms of the license for the University’s “exciplex” technology, Link will manufacture and sell highly sensitive exciplex-based diagnostic reagents worldwide. Exciplex technology offers ultra-biospecificity and significantly increased detection sensitivity over conventional systems due to negligible background signal. This license marks the start of a forward collaboration between Link and the University to develop the existing technology.
Honorary Professor Ken Douglas and Dr Elena Bichenkova, a Senior Lecturer in Medicinal Chemistry at the University of Manchester, have developed new exciplex diagnostic probes based on labelling oligonucleotides with exciplex partners that form excited-state complexes in close spatial proximity. Application of these modified oligonucleotides in diagnostic systems has been shown to discriminate DNA mutations at the level of PCR products and plasmid DNA. Professor Douglas commented: “This is a very exciting opportunity to bring together a University discovery base and this excellent company. The exciplex is a significant new area of science and we are pleased to have the expertise of Link Technologies to take this forward commercially for clinical benefit”.
Patents for this technology, covering all major market areas, are held by the University of Manchester and licensed to Link. Link Technologies has also secured the rights to any intellectual property arising from the collaboration with the University. No financial details of the agreement have been disclosed.
Most read news
Topics
Organizations

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

World's first toxicology testing strategy without animal testing adopted by OECD - Success for long-standing collaboration between BASF and Givaudan to develop and validate alternative methods
PET imaging with special tracer can detect and diagnose early Alzheimer's disease

Point-of-care diagnostics for multiple diseases, courtesy of photonics technology - New generation of diagnostic systems

Nanotechnology enables visualization of RNA structures at near-atomic resolution - Combination of nucleic acid nanotechnology and cryo-EM gives unprecedented insights into the structures of large and small RNAs

Amplification and imaging of microRNA as a biomarker to detect tumor development - Cancer Diagnostics
Genedata and Schering Expand Genomics-based Drug Discovery Collaboration Worldwide

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

Experiment-specific optimization of temperature control using auto-tuning - Fast heating rates with reduced overshoot/undershoot of the reaction temperature by auto-tuning
